Drug Profile
Research programme: ophthalmologic gene therapy - Adverum/Regeneron
Alternative Names: AVA 311Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Avalanche Biotechnologies; Regeneron Pharmaceuticals
- Developer Adverum Biotechnologies; Regeneron Pharmaceuticals
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinoschisis
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Retinoschisis in USA (Intraocular)
- 31 Dec 2019 Preclinical development is ongoing in Retinoschisis in USA (Intraocular)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Retinoschisis in USA (Intraocular)